Stephen Croskrey continued, “The expected demand growth for our PHA based products allows us to confirm our projected profitability timeline for our Kentucky operation and the Company in total. We expect our Kentucky facility, on a stand-alone basis, to become Adjusted EBITDA positive when shipments require plant capacity utilization of just over 30 percent. We expect the Company as a whole will become Adjusted EBITDA positive when our Kentucky facility reaches 70 to 80 percent capacity utilization near the start of 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNMR:
- Danimer Scientific options imply 17.3% move in share price post-earnings
- Danimer Scientific options imply 12.5% move in share price post-earnings
- Danimer Scientific options imply 28.6% move in share price post-earnings
- Danimer Scientific expands Rinnovo demonstration plant capacity
- Danimer Scientific receives continued listing standard notice from NYSE
